GPT-6 LunavsNex-N2.5-Pro (free)

Crispy Parmesan Chickpeas A crunchy, savory snack with a cheesy finish Ingredients (7): 1 can chickpeas, drained and dried 1 tablespoon olive oil ½ teaspoon salt ½ teaspoon paprika ¼ teaspoon garlic powder ¼ cup grated Parmesan 1 tablespoon lemon juice Prep time: 5 minutes Cook time: 30–35 minutes Instructions: Heat…

Pantry Moon Bars A sweet, chewy peanut butter–chocolate oat treat made with only 7 pantry staples. Ingredients Rolled oats Creamy peanut butter Honey Chocolate chips Vanilla extract Ground cinnamon Salt Instructions Heat oven to 350°F / 175°C. Line an 8-inch square pan with parchment paper.

This agreement is strongly one-sided. The enforceability of particular terms—especially the non-compete, liability provisions, and arbitration clause—depends on the governing law and the facts. The agreement does not identify a governing law, which is itself a significant gap.

Below is a general contract-risk review, not legal advice. Enforceability depends heavily on jurisdiction, contractor classification, and the exact facts. Also, even if a clause might be unenforceable, relying on that is risky because litigation/arbitration is expensive.

The main architectural risk is that the system treats collaborative editing as “write a value, then broadcast it.” That works poorly under concurrency, server failures, reconnects, and scale.

Executive summary The biggest correctness risks are: Client-clock last-write-wins is unsafe: clock skew, malicious clients, ties, and out-of-order delivery can silently lose edits.

“94% accuracy” and “predict what you want to type before you think it” Why it’s weak: This is the deck’s central technical claim, but “accuracy” is undefined: Is it word-level or character-level accuracy, measured on a fixed vocabulary or open-ended text, and under what conditions?

The 3 weakest claims are the ones most likely to be challenged in diligence: Weakest claim Why it’s weak How to strengthen it 1. “94% accuracy… works with any language, any device.” This is the biggest scientific and product credibility risk.

I would not wait six months for more data. A potentially fatal signal affecting a drug used by millions requires immediate safety assessment, prompt engagement with regulators, and a plan to inform patients and clinicians.

As CEO, I would not wait six months and I would not let the board delay disclosure while patients remain exposed to an unreported serious risk. I would treat this as a patient-safety, regulatory, legal, and trust crisis—not merely a financial-risk issue. My guiding decisions would be: Patient safety comes first.

The most important caveat is that inventing a transistor is not the same as inventing the modern semiconductor industry. A device demonstrated in 1920 might be a crude, low-power, unreliable point-contact transistor.

Starting assumption Assume the 1920 “transistor” is a usable but crude solid-state amplifier/switch: reproducible enough for telecom and radio, but noisy, low-power, temperature-sensitive, and expensive at first.